Blog

Are we ready to implement AI in healthcare?

Photo taken from lnmc.kg

Jul 23, 2024, 10:28

Are we ready to implement AI in healthcare?

Rajeev Ronanki, Lyric, shared on LinkedIn:

“‘AI, traditional machine learning, and deep learning are projected to result in net savings of up to $360 billion in healthcare spending.’

While AI continues to be a top priority for healthcare leaders, the McKinsey graph below shows that most aren’t equipped for this transformation.

It’s a priority but they aren’t ready which is a huge problem.

This is due to a lack of planning and allocated resources.

We have to continue to work to make this transformation not only feasible but accessible because its potential impact is immense.”

Douglas Flora commented on Rajeev Ronanki’s post:

“Embracing AI in Healthcare as a Strategic Imperative:

Rajeev Ronanki, this is what I’m worried about and why I’m posting here each day on these topics. Most systems approach AI like they’re shopping for a new phone system or vendor, instead of embracing it as a fundamental strategic imperative.

We need to find efficiencies across all business lines and improvements in diagnosis, risk management, access, and staff burnout.

These tools offer promising routes to improve all of those issues.

Those who figure this out early will have a head start over those approaching with more trepidation, and a decided strategic advantage.

I’d love for you to write an Op-Ed for AI in Precision Oncology about how systems can get started in responsible but more expeditious deployment of these tools?”

Source: Rajeev Ronanki/LinkedIn and Douglas Flora/LinkedIn

Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.

As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research.

He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.